Trial Profile
A Phase 1 Study of E7130 in Subjects With Solid Tumor
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs E-7130 (Primary)
- Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Eisai Co Ltd
- 30 Jan 2024 Planned End Date changed from 1 Apr 2026 to 30 Apr 2027.
- 30 Jan 2024 Planned primary completion date changed from 1 Apr 2026 to 30 Apr 2027.
- 16 Nov 2023 Planned End Date changed from 31 Oct 2025 to 1 Apr 2026.